Cancer Chemotherapy and Pharmacology

, Volume 82, Issue 5, pp 815–827 | Cite as

Development of NKG2D-based chimeric antigen receptor-T cells for gastric cancer treatment

  • Kelong Tao
  • Meng He
  • Feng Tao
  • Guangen Xu
  • Minfeng Ye
  • Yuanyuan Zheng
  • Yaoqing LiEmail author
Original Article


Gastric cancer is the third leading cause of cancer-related mortalities worldwide and mostly incurable. It remains an urgent need for novel strategies in the management of patients with advanced gastric cancer. Chimeric antigen receptor (CAR) T therapy has shown unprecedented clinical success in hematological malignancies and potential utility is going on various solid tumors like gastric cancer. In this study, a broad expression of NKG2D ligands was observed in gastric cancer cell lines, making them suitable targets for gastric cancer therapy. T cells were engineered with an NKG2D-based second-generation CAR and the resulting NKG2D-CAR-T cells showed significantly increased cytolytic activity against gastric cancer compared to untransduced T cells. In vivo, these cells can significantly suppressed the growth of established gastric cancer xenografts. Besides, cisplatin was shown to upregulate NKG2D ligand expression in gastric cancer cells and enhance the susceptibility to NKG2D-CAR-T-cell-mediated cytotoxicity. In conclusion, NKG2D-based CAR-T cells have potent in vivo and in vitro anti-tumor activities against gastric cancer and could be a new paradigm for patients with gastric cancer, either used alone or combined with chemotherapy.


NKG2D Chimeric antigen receptor Gastric cancer 


Author contributions

LYQ conceived idea, designed research and revised the manuscript; TKL and HM designed subsequent experiments, performed most of the in vitro and in vivo work, and wrote the manuscript; TF and XGG helped perform the in vivo experiments; YMF and ZYY assisted with interpretation of data and helped to perform the in vitro and in vivo work.

Compliance with ethical standards

Conflict of interest

All other authors have no conflicts of interest to disclose.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Research involving human participants

Written informed consent was obtained from each donor under a protocol approved by the Committee on Clinical investigation for the use of blood for cancer research.

Supplementary material

280_2018_3670_MOESM1_ESM.doc (186 kb)
Supplementary material 1 (DOC 186 KB)


  1. 1.
    Torre LA et al (2015) Global cancer statistics, 2012. CA Cancer J Clin 65(2):87–108CrossRefGoogle Scholar
  2. 2.
    Van Cutsem E et al (2016) Gastric cancer. Lancet 388(10060):2654–2664CrossRefGoogle Scholar
  3. 3.
    Ferlay J et al (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359–E386CrossRefGoogle Scholar
  4. 4.
    Javle M, Smyth EC, Chau I (2014) Ramucirumab: successfully targeting angiogenesis in gastric cancer. Clin Cancer Res 20(23):5875–5881CrossRefGoogle Scholar
  5. 5.
    Fujita T (2010) Trastuzumab for gastric cancer treatment. Lancet 376(9754):1735 (author reply 1735–6) CrossRefGoogle Scholar
  6. 6.
    Kochenderfer JN, Rosenberg SA (2013) Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol 10(5):267–276CrossRefGoogle Scholar
  7. 7.
    June CH et al (2018) CAR T cell immunotherapy for human cancer. Science 359(6382):1361–1365CrossRefGoogle Scholar
  8. 8.
    Chen N et al (2018) Driving CARs on the uneven road of antigen heterogeneity in solid tumors. Curr Opin Immunol 51:103–110CrossRefGoogle Scholar
  9. 9.
    Li J et al (2018) Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward. J Hematol Oncol 11(1):22CrossRefGoogle Scholar
  10. 10.
    McGilvray RW et al (2009) NKG2D ligand expression in human colorectal cancer reveals associations with prognosis and evidence for immunoediting. Clin Cancer Res 15(22):6993–7002CrossRefGoogle Scholar
  11. 11.
    Pende D et al (2002) Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Res 62(21):6178–6186PubMedGoogle Scholar
  12. 12.
    Friese MA et al (2003) MICA/NKG2D-mediated immunogene therapy of experimental gliomas. Cancer Res 63(24):8996–9006PubMedGoogle Scholar
  13. 13.
    Salih HR et al (2003) Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 102(4):1389–1396CrossRefGoogle Scholar
  14. 14.
    Barber A, Meehan KR, Sentman CL (2011) Treatment of multiple myeloma with adoptively transferred chimeric NKG2D receptor-expressing T cells. Gene Ther 18(5):509–516CrossRefGoogle Scholar
  15. 15.
    Barber A, Sentman CL (2009) Chimeric NKG2D T cells require both T cell- and host-derived cytokine secretion and perforin expression to increase tumor antigen presentation and systemic immunity. J Immunol 183(4):2365–2372CrossRefGoogle Scholar
  16. 16.
    Zhang T, Lemoi BA, Sentman CL (2005) Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy. Blood 106(5):1544–1551CrossRefGoogle Scholar
  17. 17.
    Lehner M et al (2012) Redirecting T cells to Ewing’s sarcoma family of tumors by a chimeric NKG2D receptor expressed by lentiviral transduction or mRNA transfection. PLoS One 7(2):e31210CrossRefGoogle Scholar
  18. 18.
    Turtle CJ et al (2016) CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Investig 126(6):2123–2138CrossRefGoogle Scholar
  19. 19.
    Diefenbach A, Raulet DH (2002) The innate immune response to tumors and its role in the induction of T-cell immunity. Immunol Rev 188:9–21CrossRefGoogle Scholar
  20. 20.
    Zhang T, Barber A, Sentman CL (2006) Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor. Cancer Res 66(11):5927–5933CrossRefGoogle Scholar
  21. 21.
    Alter G, Malenfant JM, Altfeld M (2004) CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods 294(1–2):15–22CrossRefGoogle Scholar
  22. 22.
    Gilham DE et al (2012) CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe. Trends Mol Med 18(7):377–384CrossRefGoogle Scholar
  23. 23.
    Zhang C et al, Phase I, Escalating-Dose (2017) Trial of CAR-T therapy targeting CEA(+) metastatic colorectal cancers. Mol Ther 25(5):1248–1258CrossRefGoogle Scholar
  24. 24.
    Junghans RP et al (2016) Phase I trial of anti-PSMA designer CAR-T cells in prostate cancer: possible role for interacting interleukin 2-T cell pharmacodynamics as a determinant of clinical response. Prostate 76(14):1257–1270CrossRefGoogle Scholar
  25. 25.
    Mason NJ et al (2016) Immunotherapy with a HER2-targeting listeria induces HER2-specific immunity and demonstrates potential therapeutic effects in a phase I trial in canine osteosarcoma. Clin Cancer Res 22(17):4380–4390CrossRefGoogle Scholar
  26. 26.
    You F et al (2016) Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified anti-MUC1 chimeric antigen receptor transduced T cells. Sci China Life Sci 59(4):386–397CrossRefGoogle Scholar
  27. 27.
    Spear P et al (2013) NKG2D CAR T-cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors. Immunol Cell Biol 91(6):435–440CrossRefGoogle Scholar
  28. 28.
    Eisenberg V et al (2017) Targeting multiple tumors using T-cells engineered to express a natural cytotoxicity receptor 2-based chimeric receptor. Front Immunol 8:1212CrossRefGoogle Scholar
  29. 29.
    Beatty GL, Moon EK (2014) Chimeric antigen receptor T cells are vulnerable to immunosuppressive mechanisms present within the tumor microenvironment. Oncoimmunology 3(11):e970027CrossRefGoogle Scholar
  30. 30.
    Mohammed S et al (2017) Improving chimeric antigen receptor-modified T cell function by reversing the immunosuppressive tumor microenvironment of pancreatic cancer. Mol Ther 25(1):249–258CrossRefGoogle Scholar
  31. 31.
    Scarfo I, Maus MV (2017) Current approaches to increase CAR T cell potency in solid tumors: targeting the tumor microenvironment. J Immunother Cancer 5:28CrossRefGoogle Scholar
  32. 32.
    Barber A, Rynda A, Sentman CL (2009) Chimeric NKG2D expressing T cells eliminate immunosuppression and activate immunity within the ovarian tumor microenvironment. J Immunol 183(11):6939–6947CrossRefGoogle Scholar
  33. 33.
    Zhang T, Sentman CL (2013) Mouse tumor vasculature expresses NKG2D ligands and can be targeted by chimeric NKG2D-modified T cells. J Immunol 190(5):2455–2463CrossRefGoogle Scholar
  34. 34.
    Dhar P, Wu JD (2018) NKG2D and its ligands in cancer. Curr Opin Immunol 51:55–61CrossRefGoogle Scholar
  35. 35.
    Koch C et al (2017) Chronic NKG2D engagement in vivo differentially impacts NK cell responsiveness by activating NK receptors. Front Immunol 8:1466CrossRefGoogle Scholar
  36. 36.
    Ikeda H, Old LJ, Schreiber RD (2002) The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev 13(2):95–109CrossRefGoogle Scholar
  37. 37.
    Schroder K et al (2004) Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol 75(2):163–189CrossRefGoogle Scholar
  38. 38.
    Zhan Y et al (2012) The inflammatory cytokine, GM-CSF, alters the developmental outcome of murine dendritic cells. Eur J Immunol 42(11):2889–2900CrossRefGoogle Scholar
  39. 39.
    Song H et al (2006) Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression. Cell Immunol 239(1):22–30CrossRefGoogle Scholar
  40. 40.
    Kamimura H et al (2012) Reduced NKG2D ligand expression in hepatocellular carcinoma correlates with early recurrence. J Hepatol 56(2):381–388CrossRefGoogle Scholar
  41. 41.
    Wu J et al (1999) An activating immunoreceptor complex formed by NKG2D and DAP10. Science 285(5428):730–732CrossRefGoogle Scholar
  42. 42.
    Garrity D et al (2005) The activating NKG2D receptor assembles in the membrane with two signaling dimers into a hexameric structure. Proc Natl Acad Sci USA 102(21):7641–7646CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Kelong Tao
    • 1
  • Meng He
    • 2
  • Feng Tao
    • 1
  • Guangen Xu
    • 1
  • Minfeng Ye
    • 1
  • Yuanyuan Zheng
    • 3
  • Yaoqing Li
    • 1
    Email author
  1. 1.Department of Gastrointestinal SurgeryShaoxing People’s Hospital (Shaoxing Hospital, Zhejiang University School of Medicine)ShaoxingPeople’s Republic of China
  2. 2.Department of Respiratory MedicineShaoxing People’s Hospital (Shaoxing Hospital, Zhejiang University School of Medicine)ShaoxingPeople’s Republic of China
  3. 3.Department of GastroenterologyShaoxing People’s Hospital (Shaoxing Hospital, Zhejiang University School of Medicine)ShaoxingPeople’s Republic of China

Personalised recommendations